Sanofi bispecific sees respiratory ph. 2 wins, eczema fail
Sanofi’s TSLP and IL-13 inhibitor has aced a pair of mid-stage studies for respiratory diseases, but missed on…
Sanofi CFO defends Hudson’s legacy, accepts R&D ‘setbacks’
As Sanofi counts down the days before its new leader arrives, the French pharma’s chief financial officer acknowledged…
Sanofi halts phase 3 autoimmune trial early over lackluster data
Sanofi has stopped a phase 3 autoimmune clinical trial early after an interim analysis found the therapy was “unlikely…